Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Rivaroxaban: An Observationalmulticenter Cohort Study Reporting the Routine Use in Adolescents & Adults with DVT

Manuela Krause, MD, Alexander Bauer, Hartmut Clausnizer, Gili Kenet, MD, Dorothee Kowalski, Verena Limperger, Ann-Kathrin Pilgrimm-Thorp, Daniela Manner, MD, Ulrike Nowak-Göttl, Prof.

Blood (2014) 124 (21): 5083.

https://doi.org/10.1182/blood.V124.21.5083.5083

Published: 2014

Journal Articles

Prognostic Parameters For Remission Of and Survival In Acquired Hemophilia A: Results Of The GTH-AH 01/2010 Multicenter Study

Andreas Tiede, MD, PhD, Jan-Malte Blumtritt, Robert Klamroth, MD, PhD, Saskia Gottstein, MD, Katharina Holstein, MD, Jürgen Heinz, MD, Rüdiger E. Scharf, MD, PhD, Angela Huth-Kühne, MD, PhD, Joachim F. Schenk, MD, PhD, Richard Greil, MD, Wolfgang A. Miesbach, MD, PhD, Ralf Ulrich Trappe, MD, PhD, Ute Scholz, MD, Daniela Manner, MD, Peter Neumeister, MD, Charis von Auer-Wegener, MD, Ulrich Kalus, MD, Klaus Leimkühler, MD, Paul Knoebl, MD

Blood (2013) 122 (21): 205.

https://doi.org/10.1182/blood.V122.21.205.205

Published: 2013

Journal Articles

Decreased ADAMTS13 Activity Levels in Patients with a Bleeding Tendency of Unknown Origin

Johanna Haselboeck, MD, Moritz Lambers, Clarissa Laszkovics, MD, Cihan Ay, MD, Daniela Manner, MD, Ingrid Pabinger, MD, Ulrike Nowak-Goettl, MD

Blood (2011) 118 (21): 1218.

https://doi.org/10.1182/blood.V118.21.1218.1218

Published: 2011

Journal Articles

Impact of Reduced Von Willebrand Factor-Cleaving Protease [ADAMTS13] In Pediatric Stroke: A Nested Case-Control Study

Ulrike Nowak-Gottl, MD, Moritz Lambers, Sabine Thedieck, Daniela Manner, MD, Rolf M. Mesters, Ralf Junker, MD, Monika Stoll, PhD

Blood (2010) 116 (21): 805.

https://doi.org/10.1182/blood.V116.21.805.805

Published: 2010

Journal Articles

Impact of Treatment Intensity and Factor VIII Products On the Development On High Titre Inhibitors in Children with Severe Hemophilia A: Results of a Non-Concurrent Cohort Study.

Karin Kurnik, MD, Susan Halimeh, MD, Daniela Manner, MD, Susanne Holzhauer, MD, Carmen Escuriola Ettingshausen, MD, Rosemarie Schobess, MD, Ulrike Nowak-Gottl, MD

Blood (2009) 114 (22): 1303.

https://doi.org/10.1182/blood.V114.22.1303.1303

Published: 2009

Journal Articles

Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.

Alfonso Iorio, MD, Susan Halimeh, MD, Christoph Bidlingmaier, MD, Leonardo R. Brandao, MD, Carmen Escuriola-Ettingshausen, MD, Neil A Goldenberg, MD, PhD, Alessandro Gringeri, MD, MSc, Susanne Holzhauer, MD, Gili Kenet, MD, PhD, Ralf Knoefler, MD, Wolfhart Kreuz, MD, Karin Kurnik, MD, Daniela Manner, MD, Emanuela Marchesini, MD, Maura Marcucci, MD, Elena Santagostino, MD, PhD, Guy Young, MD, Pier Mannuccio Mannucci, MD, Ulrike Nowak-Gottl, MD

Blood (2009) 114 (22): 3154.

https://doi.org/10.1182/blood.V114.22.3154.3154

Published: 2009

NARROW

Efficacy and Safety of Rivaroxaban: An Observationalmulticenter Cohort Study Reporting the Routine Use in Adolescents & Adults with DVT

Prognostic Parameters For Remission Of and Survival In Acquired Hemophilia A: Results Of The GTH-AH 01/2010 Multicenter Study

Decreased ADAMTS13 Activity Levels in Patients with a Bleeding Tendency of Unknown Origin

Impact of Reduced Von Willebrand Factor-Cleaving Protease [ADAMTS13] In Pediatric Stroke: A Nested Case-Control Study

Impact of Treatment Intensity and Factor VIII Products On the Development On High Titre Inhibitors in Children with Severe Hemophilia A: Results of a Non-Concurrent Cohort Study.

Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.

Email alerts

ASH Publications

American Society of Hematology

Efficacy and Safety of Rivaroxaban: An Observationalmulticenter Cohort Study Reporting the Routine Use in Adolescents & Adults with DVT

Prognostic Parameters For Remission Of and Survival In Acquired Hemophilia A: Results Of The GTH-AH 01/2010 Multicenter Study

Decreased ADAMTS13 Activity Levels in Patients with a Bleeding Tendency of Unknown Origin

Impact of Reduced Von Willebrand Factor-Cleaving Protease [ADAMTS13] In Pediatric Stroke: A Nested Case-Control Study

Impact of Treatment Intensity and Factor VIII Products On the Development On High Titre Inhibitors in Children with Severe Hemophilia A: Results of a Non-Concurrent Cohort Study.

Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only